{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(6)"],"submitter":["Ramanathan RK"],"pubmed_abstract":["<h4>Background</h4>The choice of a regimen in metastatic pancreatic cancer patients following progression on 1st line therapy is empiric and outcomes are unsatisfactory. This phase II study was performed to evaluate the efficacy of therapy selected by immunohistochemistry (IHC) in these patients following progression after one or more therapies.<h4>Methods</h4>Eligible patients underwent a percutaneous biopsy of a metastatic lesion and treatment selection was determined by IHC. The study required 35 evaluable patients (power of 86%) for detecting a true 1-year survival rate of >20%.<h4>Results</h4>A tumor biopsy was performed in 48 of 49 accrued patients. Study therapy was not given (n=13) either due to insufficient tumor on biopsy (n=8) or due to worsening cancer related symptoms after bi"],"journal":["Journal of gastrointestinal oncology"],"pagination":["925-935"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5750179"],"repository":["biostudies-literature"],"pubmed_title":["A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients."],"pmcid":["PMC5750179"],"pubmed_authors":["Posner RG","Aziz M","Xiu J","Hlavacek WS","Jameson G","Ramanathan RK","Bolejack V","Fulk M","Gatalica Z","Hidalgo M","Maitra A","Rajeshkumar NV","Hoering A","Stites EC","Weiss GJ","Barrett MT","Von Hoff DD"],"additional_accession":[]},"is_claimable":false,"name":"A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients.","description":"<h4>Background</h4>The choice of a regimen in metastatic pancreatic cancer patients following progression on 1st line therapy is empiric and outcomes are unsatisfactory. This phase II study was performed to evaluate the efficacy of therapy selected by immunohistochemistry (IHC) in these patients following progression after one or more therapies.<h4>Methods</h4>Eligible patients underwent a percutaneous biopsy of a metastatic lesion and treatment selection was determined by IHC. The study required 35 evaluable patients (power of 86%) for detecting a true 1-year survival rate of >20%.<h4>Results</h4>A tumor biopsy was performed in 48 of 49 accrued patients. Study therapy was not given (n=13) either due to insufficient tumor on biopsy (n=8) or due to worsening cancer related symptoms after bi","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Dec","modification":"2025-06-01T03:23:53.692Z","creation":"2021-02-20T04:53:45Z"},"accession":"S-EPMC5750179","cross_references":{"pubmed":["29299351"],"doi":["10.21037/jgo.2017.09.05"]}}